eligibility_summary
Adults (>=18) with histologically confirmed relapsed/refractory NHL (>=2 prior lines or relapse <=12 mo post-ASCT), ECOG <=2, measurable disease, no CNS lymphoma, >=2 wks since prior therapy, adequate organ function, consent, and contraception. Exclude: recent ASCT, prior allo-HSCT/GVHD, active malignancy, recent investigational therapy, cardiac disease, active infection, HIV, pregnant/breastfeeding, myelodysplasia, active HBV/HCV, CNS disorders, uncontrolled illness, active autoimmune disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05312801 is a Phase 1, open-label dose-escalation trial of LMY-920 (BAFF CAR-T), an autologous, gene-modified cellular therapy. Product: patient-derived CD4+/CD8+ T cells engineered via a non-viral transposon to express a BAFF-ligand chimeric antigen receptor. Mechanism: a ligand-based CAR that binds multiple BAFF receptor family members (BAFF-R/BR3, TACI, BCMA) to activate CAR-T cells and kill malignant B cells. Target cells/pathways: B-cell non-Hodgkin lymphomas expressing BAFF-R, TACI, and/or BCMA, engaging the BAFF signaling axis, designed to address disease including after CD19 CAR-T relapse. Dosing: 1–8×10^6 CAR+ cells/kg after lymphodepletion. Objective: determine MTD/RP2D and preliminary activity.